Elizabeth Abou Diwan1, Ralph I Zeitoun1, Lea Abou Haidar1, Ingolf Cascorbi2, Nathalie Khoueiry Zgheib3. 1. Faculty of Medicine, American University of Beirut, Beirut, Lebanon. 2. Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany. 3. Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Abstract
AIMS: Eight years ago, a paper-based survey was administered during the World Pharma 2010 meeting, asking about the challenges of implementing pharmacogenetics (PGx) in clinical practice. The data collected at the time gave an idea about the progress of this implementation and what still needs to be done. Since then, although there have been major initiatives to push PGx forward, PGx clinical implementation may still be facing different challenges in different parts of the world. Our aim was therefore to distribute a follow-up international survey in electronic format to elucidate an overview on the current stage of implementation, acceptance and challenges of PGx in academic institutions around the world. METHODS: This is an online anonymous LimeSurvey-based study launched on 11 November 2018. Survey questions were adapted from the initially published manuscript in 2010. An extensive web search for worldwide scientists potentially involved in PGx research resulted in a total of 1973 names. Countries were grouped based on the Human Development Index. RESULTS: There were 204 respondents from 43 countries. Despite the wide availability of PGx tests, the consistently positive attitude towards their applications and advances in the field, progress of the clinical implementation of PGx still faces many challenges all around the globe. CONCLUSIONS: Clinical implementation of PGx started over a decade ago but there is a gap in progress around the globe and discrepancies between the challenges reported by different countries, despite some challenges being universal. Further studies on ways to overcome these challenges are warranted.
AIMS: Eight years ago, a paper-based survey was administered during the World Pharma 2010 meeting, asking about the challenges of implementing pharmacogenetics (PGx) in clinical practice. The data collected at the time gave an idea about the progress of this implementation and what still needs to be done. Since then, although there have been major initiatives to push PGx forward, PGx clinical implementation may still be facing different challenges in different parts of the world. Our aim was therefore to distribute a follow-up international survey in electronic format to elucidate an overview on the current stage of implementation, acceptance and challenges of PGx in academic institutions around the world. METHODS: This is an online anonymous LimeSurvey-based study launched on 11 November 2018. Survey questions were adapted from the initially published manuscript in 2010. An extensive web search for worldwide scientists potentially involved in PGx research resulted in a total of 1973 names. Countries were grouped based on the Human Development Index. RESULTS: There were 204 respondents from 43 countries. Despite the wide availability of PGx tests, the consistently positive attitude towards their applications and advances in the field, progress of the clinical implementation of PGx still faces many challenges all around the globe. CONCLUSIONS: Clinical implementation of PGx started over a decade ago but there is a gap in progress around the globe and discrepancies between the challenges reported by different countries, despite some challenges being universal. Further studies on ways to overcome these challenges are warranted.
Authors: C H van der Wouden; A Cambon-Thomsen; E Cecchin; K C Cheung; C L Dávila-Fajardo; V H Deneer; V Dolžan; M Ingelman-Sundberg; S Jönsson; M O Karlsson; M Kriek; C Mitropoulou; G P Patrinos; M Pirmohamed; M Samwald; E Schaeffeler; M Schwab; D Steinberger; J Stingl; G Sunder-Plassmann; G Toffoli; R M Turner; M H van Rhenen; J J Swen; H-J Guchelaar Journal: Clin Pharmacol Ther Date: 2017-03 Impact factor: 6.875
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: Sze Ling Chan; Xiaohui Ang; Levana L Sani; Hong Yen Ng; Michael D Winther; Jian Jun Liu; Liam R Brunham; Alexandre Chan Journal: Br J Clin Pharmacol Date: 2016-09-19 Impact factor: 4.335
Authors: Michelle Liu; Cindy L Vnencak-Jones; Bartholomew P Roland; Cheryl L Gatto; Janos L Mathe; Shari L Just; Josh F Peterson; Sara L Van Driest; Asli O Weitkamp Journal: Clin Pharmacol Ther Date: 2020-11-15 Impact factor: 6.903
Authors: Zeina N Al-Mahayri; Lubna Q Khasawneh; Mais N Alqasrawi; Sahar M Altoum; Gohar Jamil; Sally Badawi; Dana Hamza; Lizy George; Anwar AlZaabi; Husam Ouda; Fatma Al-Maskari; Juma AlKaabi; George P Patrinos; Bassam R Ali Journal: Hum Genomics Date: 2022-09-25 Impact factor: 6.481
Authors: Juan Undurraga; Ignacio Bórquez-Infante; Nicolás A Crossley; Miguel L Prieto; Gabriela M Repetto Journal: Front Pharmacol Date: 2021-04-15 Impact factor: 5.810